Enhancing Clinical Trial Diversity: Insights on Action Plans and Regulatory Alignment
In a recent interview, Rachael Fones, director of government and public affairs at IQVIA, emphasized the importance of diversity action plans in clinical trials.
The Decline of Retail Pharmacies: A Decade of Closures and Disparities
Discover the findings of a Health Affairs study revealing the closure of one in three U.S. pharmacies since 2010, with independent pharmacies and marginalized communities hit hardest. Learn about the role of pharmacy benefit managers in this trend and its impact on healthcare disparities.
NIH’s TrialGPT: AI’s Potential in Revolutionizing Clinical Trial Recruitment
The NIH has developed TrialGPT, an AI-powered algorithm designed to match patients to suitable clinical trials more efficiently.
High Out-of-Pocket Costs Leave Nearly a Quarter of Americans Underinsured, Survey Reveals
A recent Commonwealth Fund survey highlights that 23% of working-age Americans are underinsured, facing high out-of-pocket costs that hinder access to necessary healthcare. The report also notes significant coverage gaps, with many delaying care due to cost barriers.
Abbott’s Initiative for Enhancing Diversity in Clinical Trials
Abbott's Diversity in Clinical Trials initiative outlines strategies to enhance inclusivity in clinical research, addressing barriers to participation and fostering partnerships to ensure diverse patient representation.
Enhancing Diversity in Clinical Trials: The Role of Systematic Literature Reviews in FDA’s DEI Initiatives
Systematic literature reviews (SLRs) play a crucial role in shaping inclusive and diverse clinical trials by offering insights into the demographics and health factors of various patient populations. Aligned with the FDA’s DEI initiatives, SLRs help clinical trial sponsors understand the diversity of treatment populations, ensuring trials are representative and addressing potential biases in healthcare research. By drawing on comprehensive data, SLRs support the FDA’s goals for more equitable and generalizable clinical trials.
Best practices and opportunities for advancing health equity through research
Health equity is about creating fair opportunities for all individuals to achieve optimal health. Through a structured, three-phase approach—detecting, understanding, and reducing health disparities—researchers and life sciences companies can make meaningful progress toward this goal. By leveraging high-quality data, community partnerships, and multi-level interventions, researchers can address systemic health inequities, ultimately driving better health outcomes for vulnerable populations.
Anticipated Policies and Reactions as the Healthcare Industry Braces for Second Trump Term
As Donald Trump enters his second term, the healthcare sector prepares for intensified policies affecting the Affordable Care Act, Medicaid, and industry regulations. Explore how major healthcare organizations respond and what changes might lie ahead in access, affordability, and coverage.
Navigating Challenges and Progress in Sickle Cell Disease Treatment
Explore the recent advancements and challenges in sickle cell disease treatment, including breakthroughs in gene therapy and the hurdles of accessibility, safety, and cost.
APhA Supports ECAPS Act to Preserve Essential Pharmacy Access in Underserved Communities
In the wake of increased pharmacy closures, the American Pharmacists Association (APhA) has expressed support for [...]
$1 Million Boost for Health Equity in South Florida
The Health Foundation of South Florida has invested over $1 million in nonprofit healthcare programs in [...]
Unlocking Over $1 Trillion in Economic Gains? The Economic Case for Health Equity in the U.S.
A recent report from Deloitte's Center for Health Solutions examines the economic implications of health equity [...]
Accelerating Development of Rare Genetic Disease Therapeutics
Healthcare equity is a complex problem. It requires dedicated solutions. By working with the right data partner, researchers can gather real-world data aimed at better understanding patient healthcare journeys. HEOR studies can yield new insights into disparities, presenting opportunities to create a more equitable healthcare system in which patient economic factors and geography don’t limit access to care.
Advancing Health Equity by Leveraging Social Determinants of Health Data
Healthcare equity is a complex problem. It requires dedicated solutions. By working with the right data partner, researchers can gather real-world data aimed at better understanding patient healthcare journeys. HEOR studies can yield new insights into disparities, presenting opportunities to create a more equitable healthcare system in which patient economic factors and geography don’t limit access to care.
Redefining the Patient Experience: Insights from the 2024 ATOPP Summit
At the 2024 Advanced Topics for Oncology Pharmacy Professionals (ATOPP) Summit, Richard Martin, MD, MPH, describes [...]
Elevated Cancer Risks and Barriers to Care for LGBTQ+ Community
The American Cancer Society (ACS) has recently published a report that highlights the elevated cancer risks [...]
Time to Market and Patient Access to Oncology Medicines in Turkey
A study evaluated the accessibility of oncology medicines in Turkey, analyzing the time between global marketing authorizations and local availability, including reimbursement decisions, for 40 cancer drug-indication pairs authorized between 2015 and 2020. The study's results call for policy optimization to ensure timely access to cancer treatments while maintaining healthcare system viability.
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Panelists answer top questions from their recent webinar, “Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches” about integrating patient-centered research into real-world studies.
How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications
In this episode of tHEORetically Speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.
Bridging Urban-Rural Healthcare Gaps Through Real-World Data
Medical research and clinical trials have historically favored urban communities, resulting in an underrepresentation of rural [...]
Urgent Transparency Needed in H5N1 Bird Flu Outbreaks Affecting U.S. Dairy Cattle
As H5N1 bird flu spreads across U.S. dairy cattle herds, significant concerns have arisen regarding the [...]
Debate Over U.S. Maternal Mortality Rates: Real Crisis or Data Misinterpretation?
A contentious debate has emerged among maternal health experts regarding the actual state of U.S. maternal [...]
The Stigma and Systemic Barriers Against Lifesaving Opioid Addiction Treatments in the U.S.
The opioid overdose epidemic has been devastating the U.S. for nearly three decades despite the availability [...]
Major US Pharmacy Chains to Offer Abortion Pill Mifepristone
CVS and Walgreens, the two largest pharmacy chains in the United States, announced plans to dispense [...]
Global Cholera Vaccine Shortage: A Crisis Amplified
The world faces an unprecedented cholera vaccine shortage amidst surging outbreaks across developing nations in Asia, [...]
